ClinicalTrials.gg
RecruitingNCT06657144Updated Jul 15, 2026

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

A Phase 1 interventional study of CHS-114 and Toripalimab in Metastatic Solid Tumor and Advanced Solid Tumor, sponsored by Coherus Oncology, Inc.. Recruiting at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Coherus Oncology, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,055 studies in Neoplasm Metastasis with a site in United States — 347 open to participants now, 543 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
379th of 1,864
154 · median 43
Started
2025
with 84 others
Phase 1
710 of 2,055
129 open now
Primary completion
2028-01
later than 350 of 541 live
Registered
1,897th of 2,055
by date

Among the 2,055 studies in Neoplasm Metastasis with a site in United States, this one is the 379th largest by planned enrollment of the 1,864 interventional ones that give a count, is one of 85 that started in 2025, is one of 710 in phase 1, reaches primary completion later than 350 of the 541 other live ones, and was the 1,897th registered.

Neoplasm Metastasis

4,048 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

347 of the 2,055 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,055 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

03

Conditions studied

  • Metastatic Solid Tumor
  • Advanced Solid Tumor

Keywords

  • Solid Tumors
  • Advanced Solid Tumors
  • Metastatic Solid Tumor
  • Cancer
  • Oncology
  • Tumor
  • CCR8
  • PD-1
  • Gastric cancer
  • Gastro-esophageal-junction (GEJ) cancer
  • Esophageal Adenocarcinoma (EAC)
  • Esophageal Squamous Cell Carcinoma
  • Cisplatin
  • 5 Fluorouracil (5-FU)
  • Colorectal Carcinoma (CRC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • At least 1 based on v1.1 as determined by the Investigator.
  • Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI)- (CTCAE) v5.0, except for adverse events (AEs) not constituting a safety risk per Investigator judgement.

Cohort A (2L Gastric, Gastro-esophageal-junction [GEJ], Esophageal Adenocarcinoma [EAC]) Specific Inclusion Criteria:

  • or cytologically documented unresectable, locally advanced or gastric, GEJ, or esophageal adenocarcinoma that is human epidermal growth factor receptor 2 () - negative and microsatellite stable (MSS)/proficient mismatch repair (pMMR).
  • Progressed during or after systemic therapy that includes a platinum and fluoropyrimidine doublet with or without anti-programmed death receptor 1 ()/programmed death ligand 1 (PD-L1)-directed therapy (that is, in the second line setting).
  • Consent to provide tumor tissue samples (baseline and on-treatment) is required for enrollment.

Cohort B (2L Esophageal Squamous Cell Carcinoma [ESCC]) - Specific Inclusion Criteria:

  • Histologically or cytologically documented unresectable, locally advanced or metastatic ESCC.
  • Progressed during or after first line systemic therapy including a doublet of platinum and fluoropyrimidine or paclitaxel with or without anti-PD-1/PD-L1-directed therapy or anti-CTLA-4 and anti-PD-1/PD-L1-directed combination therapy.
  • Consent to provide results from prior PD-L1 IHC assay score by FDA-approved or equivalent PD-L1 IHC diagnostic tests.
  • Consent to provide sample (baseline) is required for enrolment.

Cohort C (1L Esophageal Squamous Cell Carcinoma [ESCC]) - Specific Inclusion Criteria:

  • Histologically or cytologically documented unresectable, locally advanced or metastatic ESCC.
  • Consent to provide baseline tumor tissue is required.
  • Consent to provide results from prior PD-L1 IHC assay score by FDA-approved or equivalent PD-L1 IHC diagnostic tests.
  • Calculated ≥60 mL/min.

Cohort D, Arms D1 and D2 (4L+ Colorectal Carcinoma [CRC]) - Specific Inclusion Criteria:

  • Histologically and/or cytologically documented unresectable advanced or metastatic colorectal adenocarcinoma. RAS, BRAF, and microsatellite instability/mismatch repair status for each participant must be documented, according to country level guidelines.
  • Participants who have no available therapies with a proven clinical benefit available in the participant's country per investigator. These therapies include the following: fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapy, anti-VEGF biological therapy (eg, bevacizumab, aflibercept, ramucirumab), an anti-EGFR therapy (eg, cetuximab, panitumumab) if RAS wildtype unless right-sided, either trifluridine/tipiracil, fruqintinib or regorafenib, and a BRAF inhibitor (ie, encorafenib) in BRAF V600E mutant).
  • Participants who received oxaliplatin in the setting and developed metastatic disease during or within 6 months of completing adjuvant therapy are considered eligible without receiving oxalipatin-based therapy in the metastatic setting.
  • Consent to provide baseline tumor tissue sample is required for enrolment.

Key Exclusion Criteria:

  • History of prior other than the cancer under study that is progressing or has required active treatment within the past 3 years.
  • Symptomatic or untreated central nervous system metastases, including , requiring concurrent treatment, including but not limited to surgery, radiation, and/or .
  • Major surgery requiring general anesthesia within 28 days prior to the first dose of study treatment, still recovering from prior surgery, or with surgery scheduled during the study.
  • Prior exposure to anti-C-C motif chemokine receptor 8 (CCR8) antibody.
  • History of Grade 4 allergic or anaphylactic reaction to any monoclonal antibody (mAb) therapy or any in the study treatment.
  • Active uncontrolled bacterial, fungal, or viral infection including virus (HBV), virus (HCV), known (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
  • Any condition that, in the opinion of the Investigator or Sponsor, would interfere with the interpretation of study results.

Cohort A (2L Gastric, Gastro-esophageal-junction [GEJ], Esophageal Adenocarcinoma [EAC]) Specific Exclusion Criteria:

  • Received ≥ 2 prior systemic anticancer therapies for advanced or metastatic disease.
  • Participants at high risk for developing esophageal fistula by clinical assessment or imaging, such as prior history or associated symptoms of esophageal fistula or T4 classification assessed by endoscopic ultrasound (EUS).

Cohort B (2L Esophageal Squamous Cell Carcinoma [ESCC]) - Specific Exclusion Criteria:

  • Received ≥ 2 prior systemic anticancer therapies for advanced or metastatic disease.
  • Participants at high risk for developing esophageal fistula by clinical assessment or imaging, such as prior history or associated symptoms of esophageal fistula or T4 classification assessed by endoscopic ultrasound (EUS).

Cohort C (1L Esophageal Squamous Cell Carcinoma [ESCC]) - Specific Exclusion Criteria:

  • Received ≥ 1 prior systemic anticancer therapies for advanced or metastatic disease.
  • Participants who progressed during or within 6 months following the last dose of neoadjuvant, or perioperative therapy with curative intent.
  • Participants at high risk for developing esophageal fistula by clinical assessment or imaging, such as prior history or associated symptoms of esophageal fistula or T4 classification assessed by endoscopic ultrasound (EUS).
  • Known dihydropyrimidine dehydrogenase deficiency or thymidine synthase gene polymorphism predisposing the participant to 5-FU toxicity.
  • Known allergies to 5-FU or cisplatin.

Note: Other protocol-specified inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    Cohort A - Arm A1: CHS-114 Dose A + Toripalimab

    Participants will be treated with dose A of CHS-114 administered as an intravenous (IV) infusion in combination with toripalimab every 3 weeks (Q3W).

    Drug: CHS-114 · Drug: Toripalimab

  • Experimental
    Cohort A - Arm A2: CHS-114 Dose B + Toripalimab

    Participants will be treated with dose B of CHS-114 administered as an IV infusion in combination with toripalimab Q3W.

    Drug: CHS-114 · Drug: Toripalimab

  • Experimental
    Cohort B - Arm B1: CHS-114 Dose A + Toripalimab

    Participants will be treated with dose A of CHS-114 administered as an IV infusion in combination with toripalimab Q3W.

    Drug: CHS-114 · Drug: Toripalimab

  • Experimental
    Cohort B - Arm B2: CHS-114 Dose B + Toripalimab

    Participants will be treated with dose B of CHS-114 administered as an IV infusion in combination with toripalimab Q3W.

    Drug: CHS-114 · Drug: Toripalimab

  • Experimental
    Cohort C - Arm C: CHS-114 Dose B + Toripalimab + 5 fluorouracil (5 FU) + Cisplatin

    Participants will be treated with dose B of CHS-114 administered as an IV infusion in combination with toripalimab, 5 FU, and cisplatin Q3W.

    Drug: CHS-114 · Drug: Toripalimab · Drug: 5 Fluorouracil · Drug: Cisplatin

  • Experimental
    Experimental: Cohort D - Arm D1 (Liver Mets): CHS-114 + Toripalimab

    Participants will be treated with CHS-114 administered as an IV infusion in combination with toripalimab Q3W.

    Drug: CHS-114 · Drug: Toripalimab

  • Experimental
    Experimental: Cohort D - Arm D2 (Non-Liver Mets): CHS-114 + Toripalimab

    Participants will be treated with CHS-114 administered as an IV infusion in combination with toripalimab Q3W.

    Drug: CHS-114 · Drug: Toripalimab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: From first dose of study drug until 90 days after the last dose of study drug (up to approximately 2.25 years)

Secondary outcomes

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Based on Investigator Assessment

    ORR is defined as percentage of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1.

    Time frame: Up to approximately 2.25 years

  2. Duration of Response (DOR) Per RECIST v1.1 Based on Investigator Assessment

    DOR is defined as the time from first documentation of response (CR or PR) to first radiographic documentation of progressive disease or death due to any cause according to RECIST v1.1.

    Time frame: Up to approximately 2.25 years

  3. Disease Control Rate (DCR) Per RECIST v1.1 Based on Investigator Assessment

    DCR is defined as the percentage of participants who achieve a confirmed CR or PR or stable disease (SD) lasting ≥ 12 weeks according to RECIST v1.1.

    Time frame: Up to approximately 2.25 years

  4. Progression-free Survival (PFS) Per RECIST v1.1 Based on Investigator Assessment

    PFS is defined as the time of the first dose of study treatment to the time of the first documented unequivocal disease progression assessed per RECIST v1.1 or death due to any cause (whichever occurs first).

    Time frame: Up to approximately 2.25 years

  5. Landmark PFS Rates

    Time frame: Months 6, 9, and 12

  6. Maximum Observed Serum Concentration (Cmax) of CHS-114

    Time frame: Up to approximately 2.25 years (pre-infusion and up to 336 hours post-infusion)

  7. Time to Reach Cmax (Tmax) of CHS-114

    Time frame: Up to approximately 2.25 years (pre-infusion and up to 336 hours post-infusion)

  8. Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of CHS-114

    Time frame: Up to approximately 2.25 years (pre-infusion and up to 336 hours post-infusion)

  9. Number of Participants With Anti-drug Antibodies (ADAs)

    Time frame: Up to approximately 2.25 years

07

Study locations

28 of 30 sites recruiting
08

References and documents

Publications

  • Wang X, Kapoor VN, Chin DJ, Klakamp SL, Baruffaldi F, Mohan JF, Haines R, Dulak A, Panduro M, Ren Y, Masia R, Hill JA, LaVallee TM, Rajasekaran N. CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses. Mol Cancer Ther. 2026 May 4;25(5):685-700. doi: 10.1158/1535-7163.MCT-25-0367. PubMed 41423415 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jan 2028, 33 months after the start.

Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 33 months is below that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2024
First posted
Oct 24, 2024
StartActual
Apr 1, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06657144
Lead sponsor
Coherus Oncology, Inc.
Responsible party
Sponsor
First posted
Oct 24, 2024
Start date
Apr 1, 2025
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jul 15, 2026

Study contacts

Clinical Operations Team
Contact
clinicaltrials@coherus.com
+1-800-794-5434
Study Director
study director · Coherus Oncology

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Toripalimab

Start the discussion